Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Apr 30;4(4):CD004827.
doi: 10.1002/14651858.CD004827.pub5.

Probiotics for the prevention of pediatric antibiotic-associated diarrhea

Qin Guo  1 , Joshua Z Goldenberg, Claire Humphrey, Regina El Dib, Bradley C Johnston
Affiliations
Meta-Analysis

Probiotics for the prevention of pediatric antibiotic-associated diarrhea

Qin Guo et al. Cochrane Database Syst Rev. .

Abstract

Background: Antibiotics alter the microbial balance commonly resulting in antibiotic-associated diarrhea (AAD). Probiotics may prevent AAD via providing gut barrier, restoration of the gut microflora, and other potential mechanisms of action.

Objectives: The primary objectives were to assess the efficacy and safety of probiotics (any specified strain or dose) used for the prevention of AAD in children.

Search methods: MEDLINE, Embase, CENTRAL, CINAHL, and the Web of Science (inception to 28 May 2018) were searched along with registers including the ISRCTN and Clinicaltrials.gov. We also searched the NICE Evidence Services database as well as reference lists from relevant articles.

Selection criteria: Randomized, parallel, controlled trials in children (0 to 18 years) receiving antibiotics, that compare probiotics to placebo, active alternative prophylaxis, or no treatment and measure the incidence of diarrhea secondary to antibiotic use were considered for inclusion.

Data collection and analysis: Study selection, data extraction, and risk of bias assessment were conducted independently by two authors. Dichotomous data (incidence of AAD, adverse events) were combined using a pooled risk ratio (RR) or risk difference (RD), and continuous data (mean duration of diarrhea) as mean difference (MD), along with corresponding 95% confidence interval (95% CI). We calculated the number needed to treat for an additional beneficial outcome (NNTB) where appropriate. For studies reporting on microbiome characteristics using heterogeneous outcomes, we describe the results narratively. The certainty of the evidence was evaluated using GRADE.

Main results: Thirty-three studies (6352 participants) were included. Probiotics assessed included Bacillus spp., Bifidobacterium spp., Clostridium butyricum, Lactobacilli spp., Lactococcus spp., Leuconostoc cremoris, Saccharomyces spp., orStreptococcus spp., alone or in combination. The risk of bias was determined to be high in 20 studies and low in 13 studies. Complete case (patients who did not complete the studies were not included in the analysis) results from 33 trials reporting on the incidence of diarrhea show a precise benefit from probiotics compared to active, placebo or no treatment control.After 5 days to 12 weeks of follow-up, the incidence of AAD in the probiotic group was 8% (259/3232) compared to 19% (598/3120) in the control group (RR 0.45, 95% CI 0.36 to 0.56; I² = 57%, 6352 participants; NNTB 9, 95% CI 7 to 13; moderate certainty evidence). Nineteen studies had loss to follow-up ranging from 1% to 46%. After making assumptions for those lost, the observed benefit was still statistically significant using an extreme plausible intention-to-treat (ITT) analysis, wherein the incidence of AAD in the probiotic group was 12% (436/3551) compared to 19% (664/3468) in the control group (7019 participants; RR 0.61; 95% CI 0.49 to 0.77; P <0.00001; I² = 70%). An a priori available case subgroup analysis exploring heterogeneity indicated that high dose (≥ 5 billion CFUs per day) is more effective than low probiotic dose (< 5 billion CFUs per day), interaction P value = 0.01. For the high dose studies the incidence of AAD in the probiotic group was 8% (162/2029) compared to 23% (462/2009) in the control group (4038 participants; RR 0.37; 95% CI 0.30 to 0.46; P = 0.06; moderate certainty evidence). For the low dose studies the incidence of AAD in the probiotic group was 8% (97/1155) compared to 13% (133/1059) in the control group (2214 participants; RR 0.68; 95% CI 0.46 to 1.01; P = 0.02). Again, assumptions for loss to follow-up using an extreme plausible ITT analysis was statistically significant. For high dose studies the incidence of AAD in the probiotic group was 13% (278/2218) compared to 23% (503/2207) in control group (4425 participants; RR 0.54; 95% CI 0.42 to 0.70; P <0.00001; I² = 68%; moderate certainty evidence).None of the 24 trials (4415 participants) that reported on adverse events reported any serious adverse events attributable to probiotics. Adverse event rates were low. After 5 days to 4 weeks follow-up, 4% (86/2229) of probiotics participants had an adverse event compared to 6% (121/2186) of control participants (RD 0.00; 95% CI -0.01 to 0.01; P < 0.00001; I² = 75%; low certainty evidence). Common adverse events included rash, nausea, gas, flatulence, abdominal bloating, and constipation.After 10 days to 12 weeks of follow-up, eight studies recorded data on our secondary outcome, the mean duration of diarrhea; with probiotics reducing diarrhea duration by almost one day (MD -0.91; 95% CI -1.38 to -0.44; P <0.00001; low certainty evidence). One study reported on microbiome characteristics, reporting no difference in changes with concurrent antibiotic and probiotic use.

Authors' conclusions: The overall evidence suggests a moderate protective effect of probiotics for preventing AAD (NNTB 9, 95% CI 7 to 13). Using five criteria to evaluate the credibility of the subgroup analysis on probiotic dose, the results indicate the subgroup effect based on high dose probiotics (≥ 5 billion CFUs per day) was credible. Based on high-dose probiotics, the NNTB to prevent one case of diarrhea is 6 (95% CI 5 to 9). The overall certainty of the evidence for the primary endpoint, incidence of AAD based on high dose probiotics was moderate due to the minor issues with risk of bias and inconsistency related to a diversity of probiotic agents used. Evidence also suggests that probiotics may moderately reduce the duration of diarrhea, a reduction by almost one day. The benefit of high dose probiotics (e.g. Lactobacillus rhamnosus orSaccharomyces boulardii) needs to be confirmed by a large well-designed multi-centered randomized trial. It is premature to draw firm conclusions about the efficacy and safety of 'other' probiotic agents as an adjunct to antibiotics in children. Adverse event rates were low and no serious adverse events were attributable to probiotics. Although no serious adverse events were observed among inpatient and outpatient children, including small studies conducted in the intensive care unit and in the neonatal unit, observational studies not included in this review have reported serious adverse events in severely debilitated or immuno-compromised children with underlying risk factors including central venous catheter use and disorders associated with bacterial/fungal translocation.

PubMed Disclaimer

Conflict of interest statement

Qin Guo: None known.

Joshua Z Goldenberg: None known.

Claire Humphrey: None known.

Regina El Dib: None known.

Bradley C Johnston: None known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Funnel plot of comparison: 1 any specific probiotic versus control (placebo, active or no treatment), outcome: 1.6 Incidence of Diarrhea: Complete case ‐ fixed effects
5
5
Funnel plot of comparison: 1 Probiotics versus control, outcome: 1.1 Incidence of diarrhea: Complete case.
6
6
Forest plot of comparison: 1 Probiotics versus control, outcome: 1.1 Incidence of diarrhea: Complete case.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Arvola 1999 {published data only}
    1. Arvola T, Laiho K, Torkkeli S, Mykkanen H, Salminen S, Maunula L, et al. Prophylactic Lactobacillus GG reduces antibiotic‐associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999;104(5):e64. - PubMed
Benhamou 1999 {published data only}
    1. Benhamou PH, Berlier P, Danjou G, Plique O, Jessueld D, DuPont C. Antibiotic‐associated diarrhoea in children: A computer monitored double‐blind outpatients trial comparing a protective and a probiotic agent. Médecine & Chirurgie Digestives 1999;28(4):163‐8.
Conway 2007 {published data only}
    1. Conway S, Hart A, Clark A, Harvey I. Does eating yogurt prevent antibiotic‐associated diarrhoea? A placebo‐controlled randomised controlled trial in general practice. British Journal of General Practice 2007;57(545):953‐9. - PMC - PubMed
Correa 2005 {published data only}
    1. Corrêa NB, Péret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic‐associated diarrhea in infants. Journal of Clinical Gastroenterology 2005;39(5):385‐9. - PubMed
Destura unpublished {published data only}
    1. Destura RV. Bacillus clausii in preventing antibiotic‐associated diarrhea among Filipino infants and children: A multi‐center, randomized, open‐label clinical trial of efficacy and safety. unpublished.
Dharani 2017 {published and unpublished data}
    1. Dharnai S, Nirmala P, Ramanathan R, Vanitha S. Comparative study of efficacy and safety of azithromycin alone and in combination with probiotic in the treatment of impetigo in children. International Journal of Current Pharmaceutical Research 2017;9(6):52‐5.
Erdeve 2004 {published data only}
    1. Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. Journal of Tropical Pediatrics 2004;50(4):234‐6. - PubMed
Esposito 2017 {published and unpublished data}
    1. Esposito C, Roberti A, Turrà F, Cerulo M, Severino G, Settimi A, et al. Frequency of antibiotic‐associated diarrhea and related complications in pediatric patients who underwent hypospadias repair: a comparative study using probiotics vs placebo. Probiotics Antimicrob Proteins 2018;10:323–8. - PubMed
Fox 2015 {published data only}
    1. Fox M, Ahuja K, Robertson I, Ball M, Eri R. Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double blind,randomised, placebo‐controlled study. BMJ Open 2015;5:e006474. - PMC - PubMed
Georgieva 2015 {published and unpublished data}
    1. Georgieva M, Pancheva R, Rasheva N, Usheva N, Ivanova L, Koleva K. Use of the probiotic Lactobacillus reuteri DSM 17938 in the prevention of antibiotic‐associated infections in hospitalized Bulgarian children: a randomized, controlled trial. Journal of IMAB 2015;21(4):895‐900.
Jindal 2017 {published and unpublished data}
    1. Jindal M, Goyal Y, lata S, Sharma R K. Preventive role of probiotic in antibiotic associated diarrhoea in children. Indian Journal of Public Health Research and Development 2017;3:66‐9.
Jirapinyo 2002 {published data only}
    1. Jirapinyo P, Densupsoontorn N, Thamonsiri N, Wongarn R. Prevention of antibiotic‐associated diarrhea in infants by probiotics. Journal of the Medical Association of Thailand 2002;85 Suppl 2:s739‐42. - PubMed
King 2010 {unpublished data only}
    1. King S, Walton S, Chung A, Vidal R, Falkos S, Bonafante E. A randomized, double‐blind, placebo controlled trial to assess the efficacy of Lactobacillus GG in the prevention of antibiotic‐associated diarrhea in the pediatric intensive care unit. Unpublished. (Published conference abstract and email with authors).
Kodadad 2013 {published data only}
    1. Ahmad K, Fatemeh F, Mehri N, Maryam S. Probiotics for the Treatment of Pediatric Helicobacter Pylori Infection:A Randomized Double Blind Clinical Trial. Iranian Journal of Pediatrics 2013;23(1):79‐84. - PMC - PubMed
Kolodziej 2018 {published data only}
    1. Kołodziej M, Szajewska H. Lactobacillus reuteri DSM 17938 in the prevention of antibiotic‐associated diarrhea in children: a randomized clinical trial. Clinical Microbiology and Infection 2018 Aug 24 [Epub ahead of print]. [DOI: 10.1016/j.cmi.2018.08.017] - DOI - PubMed
Kotowska 2005 {published data only}
    1. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea in children: a randomized double‐blind placebo‐controlled trial. Alimentary Pharmacology and Therapeutics 2005;21(5):583‐90. - PubMed
LaRosa 2003 {published data only}
    1. LaRosa M, Bottaro G, Gulino N, Gambuzza F, Forti F, Ini G, et al. Prevention of antibiotic‐associated diarrhea with Lactobacillus sporogens and fructo‐oligosaccharides in children: A multicentric double‐blind vs placebo study. Minerva Pediatrica 2003;55(5):447‐52. - PubMed
Merenstein 2009 {published data only}
    1. Merenstein DJ, Foster J, D'Amico F. A randomized clinical trial measuring the influence of kefir on antibiotic‐associated diarrhea: the measuring the influence of Kefir (MILK) Study. Archives of Pediatrics & Adolescent Medicine 2009;163(8):750‐4. - PubMed
Olek 2017 {published and unpublished data}
    1. Olek A, Woynarowski M, Ahrén IL, Kierkuś J, Socha P, Larsson N, Önning G. Efficacy and Safety of Lactobacillus plantarum DSM 9843 (LP299V) in the Prevention of Antibiotic‐Associated Gastrointestinal Symptoms in Children—Randomized, Double‐Blind, Placebo‐Controlled Study. Journal of Pediatrics 2017;186:82‐6. - PubMed
Peng 2014 {published and unpublished data}
    1. Peng F, Wu S Y. Oral Saccharomyces boulardii combined with conventional antibiotic therapy for treatment of secondary diarrhea in neonates [口服布拉酵母菌联合常规抗生素治疗对新生儿患者继发腹泻的治疗作用]. Shijie Huaren Xiaohua Zazhi 2014;22(28):4364‐7.
Ruszczynski 2008 {published data only}
    1. Ruszczyński M, Radzikowski A, Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic‐associated diarrhoea in children. Alimentary Pharmacology and Therapeutics 2008;28(1):154‐61. - PubMed
Saneeyan 2011 {published data only}
    1. Saneeyan H, Layegh S, Rahimi H. Effectivness of probiotic on treatment of Helicobacter pylori infection in children. Journal of Isfahan Medical School 2011;29(146):882‐9.
Shan 2013 {published data only}
    1. Shan L, Hou Z, Wang F, Liu N, Chen L, Shu H, et al. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Beneficial Microbes 2013;4(4):329‐34. - PubMed
Sykora 2005 {published data only}
    1. Sykora J, Valeckova K, Amlerova J, Siala K, Dedek P, Watkins S, et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN‐114 001 and the eradication of H. pylori in children: a prospective randomized double‐blind study. Journal of Clinical Gastroenterology 2005;39(8):692‐8. - PubMed
Szajewska 2009 {published data only}
    1. Szajewska H, Albrecht P, Topczewska‐Cabanek A. Randomized, double‐blind, placebo‐controlled trial: effect of Lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. Journal of Pediatric Gastroenterology and Nutrition 2009;48(4):431‐6. - PubMed
Szymanski 2008 {published data only}
    1. Szymański H, Armańska M, Kowalska‐Duplaga K, Szajewska H. Bifidobacterium longum PL03, Lactobacillus rhamnosus KL53A, and Lactobacillus plantarum PL02 in the prevention of antibiotic‐associated diarrhea in children: a randomized controlled pilot trial. Digestion 2008;78(1):13‐7. - PubMed
Tankanow 1990 {published data only}
    1. Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. A double‐blind, placebo‐controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin‐induced diarrhea. DICP: The Annals of Pharmacotherapy 1990;24(4):382‐4. - PubMed
Vanderhoof 1999 {published data only}
    1. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic‐associated diarrhea in children. Journal of Pediatrics 1999;135(5):564‐8. - PubMed
Wan 2017 {published and unpublished data}
    1. Wan CM, Yu H, Liu G, Xu HM, Mao ZQ, Xu Y, et al. A multicenter randomized controlled study of Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhea in infants and young children [布拉酵母菌预防婴幼儿抗生素相关性腹泻的多中心随机对照研究]. Zhonghua Er Ke Za Zhi 2017;55(5):349‐54. - PubMed
Zakordonets 2016 {published and unpublished data}
    1. Zakordonets L, Tolstanova G, Yankovskiy D, Dyment H, Kramarev S. Different regimes of multiprobiotic for prevention of immediate and delayed side effects of antibiotic therapy In children. Research Journal of Pharmaceutical, Biological and Chemical Sciences 2016;7(3):2194‐201.
Zhang 2015 {published and unpublished data}
    1. Zhang B, Xu Y Zh, Deng Zh H, Chu B, Jiang LR, Vandenplas Y. The efficacy of Saccharomyces boulardii CNCM I‐745 in addition to standard Helicobacter pylori eradication treatment in children. Journal of Pediatric Gastroenterology and Nutrition 2015;18(1):17‐22. - PMC - PubMed
Zhao 2014 {published data only}
    1. Zhao HM, Ou‐Yang HJ, Duan BP, Xu B, Chen ZY, Tang J, et al. Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children. Zhongguo Dang Dai Er Ke Za Zhi 2014;16(3):230‐3. - PubMed
Zheng 2012 {published data only}
    1. Zheng YJ, Mao ZQ, Wu QB, Liu CY, Huang ZH, Huang YK, et al. Multicenter, randomized, controlled clinical trial on preventing antibiotic‐associated diarrhea in children with pneumonia using the live Clostridium butyricum and Bifidobacterium combined powder. Chinese Journal of Pediatrics 2012;50:732‐6. - PubMed

References to studies excluded from this review

Adam 1977 {published data only}
    1. Adam J, Barret A, Barret‐Bellet C. [Essais cliniques controles en double insu de l’ultra‐levure lyphilisee: etude multicentrique par 25 medicins de 388 cas]. Gazette Médicale de France 1977;84:2072‐8.
Beausoleil 2007 {published data only}
    1. Beausoleil M, Fortier N, Guénette S, L'ecuyer A, Savoie M, Franco M, et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic‐associated diarrhea: a randomized, double‐blind, placebo‐controlled trial. Canadian Journal of Gastroenterology 2007;21(11):732‐6. - PMC - PubMed
Brunser 2006 {published data only}
    1. Brunser O, Gotteland M, Cruchet S, Figueroa G, Garrido D, Steenhout P. Effect of a milk formula with prebiotics on the intestinal microbiota of infants after an antibiotic treatment. Pediatric Research 2006;59(3):451‐6. - PubMed
Can 2006 {published data only}
    1. Can M, Besirbellioglu BA, Avci IY, Beker CM, Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhea: a prospective study. Medical Science Monitor 2006;12(4):PI19‐22. - PubMed
Chapoy 1985 {published data only}
    1. Chapoy P. Treatment of acute infantile diarrhea: controlled trial of Saccharomyces boulardii [Traitement des diarrhees aigues infantiles: essai controle de Saccharomces boulardii]. Annales de Pédiatrie 1985;32(6):561‐3. - PubMed
Contreras 1983 {published data only}
    1. Contreras G, Corti C, Cassani E. Lactobacillus acidophilus in childhood diarrhea. Compendium de Investigaciones Clínicas Latinoamericanas 1983;3:114‐6.
Czerwionka 2006 {published data only}
    1. Czerwionka‐Szaflarska M, Kuczynska R, Mierzwa G, Bala G, Murawska S. Effect of probiotic bacteria supplementation on the tolerance of Helicobacter pylori eradication therapy in children and youth. Pediatria Polska 2006;81(5):334‐41.
Dajani 2013 {published data only}
    1. Dajani AI, Abu Hammour AM, Yang DH, Chung PC, Nounou MA, Yuan KY, et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy?. Saudi Journal of Gastroenterology 2013;19(3):113‐20. - PMC - PubMed
Daschner 1979 {published data only}
    1. Daschner F, Kienitz M. A Saccharomyces preparation for diarrhea? [Perenterol bei Durchfallen?]. Gynakol Prax 1979;3(3):530‐1.
Duman 2005 {published data only}
    1. Duman DG, Bor S, Ozütemiz O, Sahin T, Oğuz D, Iştan F, et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic‐associated diarrhoea due to Helicobacter pylori eradication. European Journal of Gastroenterology & Hepatology 2005;17(12):1357‐61. - PubMed
Erdeve 2005 {published data only}
    1. Erdeve O, Tiras U, Dallar Y, Savas S. Saccaromyces boulardii and antibiotic‐associated diarrhoea in children. Alimentary Pharmacology and Therapeutics 2005;21(12):1508‐9. - PubMed
Guandalini 1988 {published data only}
    1. Guandalini S, Fasano A. Antibiotic‐induced diarrhea. Rivista Italiana di Pediatria 1988;14(2):145‐9.
Honeycutt 2007 {published data only}
    1. Honeycutt TC, Khashab M, Wardrop RM 3rd, McNeal‐Trice K, Honeycutt AL, Christy CG, et al. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo‐controlled trial. Pediatric Critical Care Medicine 2007;8(5):452‐8. - PubMed
Hosjak 2010 {published data only}
    1. Hojsak I, Abdović S, Szajewska H, Milosević M, Krznarić Z, Kolacek S. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics 2010;125(5):e1171‐7. - PubMed
Hurduc 2009 {published data only}
    1. Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatrica 2009;98(1):127‐31. - PubMed
Imase 2008 {published data only}
    1. Imase K, Takahashi M, Tanaka A, Tokunaga K, Sugano H, Tanaka M, et al. Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. Microbiology and Immunology 2008;52(3):156‐61. - PubMed
Islek 2015 {published data only}
    1. Islek A, Sayar E, Yilmaz A, Artan R. Bifidobacterium lactis B94 plus inulin for Treatment of Helicobacter pylori infection in children: does it increase eradication rate and patient compliance?. Acta Gastroenterologica Belgica 2015;78(3):282‐6. - PubMed
Kim 2008 {published data only}
    1. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, et al. The effects of probiotics on PPI‐triple therapy for Helicobacter pylori eradication. Helicobacter 2008;13(4):261‐8. - PubMed
Kleinkauf 1959 {published data only}
    1. Kleinkauf I. The use of resistant acidophilus strains during antibiotic therapy [Erfahrungen mit der Anwendung resistenter Acidophilusstämme während der antibiotischen Therapie]. Archiv für Kinderheilkunde 1959;160:51‐60.
Koning 2008 {published data only}
    1. Koning CJ, Jonkers DM, Stobberingh EE, Mulder L, Rombouts FM, Stockbrügger RW. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. American Journal of Gastroenterology 2008;103(1):178‐89. - PubMed
Lei 2006 {published data only}
    1. Lei V, Friis H, Michaelsen KF. Spontaneously fermented millet product as a natural probiotic treatment for diarrhoea in young children: an intervention study in northern Ghana. International Journal of Food Microbiology 2006;110(3):246‐53. - PubMed
Lin 2009 {published data only}
    1. Lin JS, Chiu YH, Lin NT, Chu CH, Huang KC, Liao KW, et al. Different effects of probiotic species/strains on infections in preschool children: A double‐blind, randomized,controlled study. Vaccine 2009;27(7):1073‐9. - PubMed
Lionetti 2006 {published data only}
    1. Lionetti E, Miniello VL, Castellaneta SP, Magistá AM, Canio A, Maurogiovanni G, et al. Lactobacillus reuteri therapy to reduce side‐effects during anti‐Helicobacter pylori treatment in children: a randomized placebo controlled trial. Alimentary Pharmacology and Therapeutics 2006;24(10):1461‐8. - PubMed
McFarland 2005 {published data only}
    1. McFarland LV. Can Saccharomyces boulardii prevent antibiotic‐associated diarrhea in children?. Nature Clinical Practice Gastroenterology & Hepatology 2005;2(6):262‐3. - PubMed
Michail 2011 {published data only}
    1. Michail S, Kenche H. Gut microbiota is not modified by Randomized, Double‐blind, Placebo‐controlled Trial of VSL#3 in Diarrhea‐predominant Irritable Bowel Syndrome. Probiotics Antimicrob Proteins 2011;3(1):1‐7. - PMC - PubMed
Michielutti 1996 {published data only}
    1. Michielutti F, Bertini B, Presciuttini B, Andreotti G. Clinical assessment of a new oral bacterial treatment for children with acute diarrhea [Valutazione clinica di un nuovo batterioterapico orale in pazienti di eta pediatrica con dirrea acuta]. Minerva Medica 1996;87(11):545‐50. - PubMed
Morrow 2010 {published data only}
    1. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator‐associated pneumonia: a blinded, randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine 2010;182(8):1058‐64. - PMC - PubMed
Nista 2004 {published data only}
    1. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, et al. Bacillus clausii therapy to reduce side‐effects of anti‐Helicobacter pylori treatment: randomized, double‐blind,placebo controlled trial. Alimentary Pharmacology & Therapeutics 2004;20(10):1181‐8. - PubMed
Pancheva 2009 {published data only}
    1. Pancheva R, Stoeva K, Georgieva M, Bliznakova D, Gylybova M, Ivanova L, et al. A randomized controlled trial on the effect of a combination of Lactobacillus acidophilus, Lactobacillus delbruecki subsp. Bulgaricus and Bifidobacterium bifidumin the prophylaxis of vomiting and diarrhoea of hospitalised children 1 to 7 years of age. Journal of Pediatric Gastroenterology and Nutrition 2009;48(Suppl 3):E111.
Parfenov 2005 {published data only}
    1. Parfenov AI, Ruchkina IN, Tsaregorodtsev TM, Serova TI. Clinical efficacy of Actimel for patients with the irritated bowel syndrome with prevailing diarrhea. Experimental & Clinical Gastroenterology 2005;5:45‐52. - PubMed
Park 2007 {published data only}
    1. Park SK, Park DI, Choi JS, Kang MS, Park JH, Kim HJ, et al. The effect of probiotics on Helicobacter pylori eradication. Hepatogastroenterology 2007;54(79):2032‐6. - PubMed
Penna 2009 {published data only}
    1. Penna FGC, Loures MD, Carvalho AB, Pimenta JR, Figueiredo PCP, Filho LAP, et al. Lack of effect of Lactobacillus delbrueckii H2B20 in the prevention of diarrhea in children hospitalized for short period [La falta de efecto de Lactobacillus delbrueckii H2B20 en la prevención de la diarrea en niños hospitalizados a corto plazo]. Pediatria (São Paulo) 2009;31:76‐80.
Plewinska 2006 {published data only}
    1. Plewińska EM, Płaneta‐Małecka I, Bąk‐Romaniszyn L, Czkwianianc E, Małecka‐Panas E. Probiotics in the treatment of Helicobacter pylori infection in children. Gastroenterologia Polska 2006;13:315‐9.
Saavedra 1994 {published data only}
    1. Saavedra NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994;344(8929):1046‐9. - PubMed
Savas‐Erdeve 2009 {published data only}
    1. Savas‐Erdeve S, Gökay S, Dallar Y. Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics 2009;51(3):220‐4. - PubMed
Schrezenmeir 2004 {published data only}
    1. Schrezenmeir J, Heller K, McCue M, Llamas C, Lam W, Burow H, et al. Benefits of oral supplementation with and without synbiotics in young children with acute bacterial infections. Clinical Pediatrics 2004;43(3):239‐49. - PubMed
Seki 2003 {published data only}
    1. Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, et al. Prevention of antibiotic‐associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatrics International 2003;45(1):86‐90. - PubMed
Siitonen 1990 {published data only}
    1. Siitonen S, Vapaatalo H, Salminen S, Gordin A, Saxelin M, Wikberg R, et al. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. Annals of Medicine 1990;22(1):57‐9. - PubMed
Simakachorn 2011 {published data only}
    1. Simakachorn N, Bibiloni R, Yimyaem P, Tongpenyai Y, Varavithaya W, Grathwohl D, et al. Tolerance, safety, and effect on the faecal microbiota of an enteral formula supplemented with pre‐ and probiotics in critically ill children. Journal of Pediatric Gastroenterology and Nutrition 2011;53(2):174‐81. - PubMed
Srinivasan 2006 {published data only}
    1. Srinivasan R, Meyer R, Padmanabhan R, Britto J. Clinical safety of Lactobacillus casei shirota as a probiotic in critically ill children. Journal of Pediatric Gastroenterology and Nutrition 2006;42(2):171‐3. - PubMed
Szajewka 2001 {published data only}
    1. Szajewska H, Kotowska M, Mrukowicz JZ, Armańska M, Mikołajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. Journal of Pediatrics 2001;138(3):361‐5. - PubMed
Thomas 2001 {published data only}
    1. Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM. Lack of effect of Lactobacillus GG on antibiotic‐associated diarrhea: a randomized, placebo‐controlled trial. Mayo Clinic Proceedings 2001;76(9):883‐9. - PubMed
Tolone 2012 {published data only}
    1. Tolone S, Pellino V, Vitaliti G, Lanzafame A, Tolone C. Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Italian Journal of Pediatrics 2012;38:63. - PMC - PubMed
Valsecchi 2014 {published data only}
    1. Valsecchi C, Marseglia A, Montagna L, Tagliacarne SC, Elli M, Licari A, et al. Evaluation of the effects of a probiotic supplementation with respect to placebo on intestinal microflora and secretory IgA production, during antibiotic therapy, in children affected by recurrent airway infections and skin symptoms. Journal of Biological Regulators and Homeostatic Agents 2014;28(1):117‐24. - PubMed
Wanke 2012 {published data only}
    1. Wanke M, Szajewska H. Lack of an effect of Lactobacillus reuteri DSM 17938 in preventing nosocomial diarrhea in children: a randomized, double‐blind, placebo‐controlled trial. Journal of Pediatrics 2012;161(1):40‐3. - PubMed
Weizman 2005 {published data only}
    1. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005;115(1):5‐9. - PubMed
Wenus 2008 {published data only}
    1. Wenus C, Goll R, Loken EB, Biong AS, Halvorsen DS, Florholmen J. Prevention of antibiotic‐associated diarrhoea by a fermented probiotic milk drink. European Journal of Clinical Nutrition 2008;62(2):299‐301. - PubMed
Witsell 1995 {published data only}
    1. Witsell DL, Garrett CG, Yarbrough WG, Dorrestein SP, Drake AF, Weissler MC. Effect of Lactobacillus acidophilus on antibiotic‐associated gastrointestinal morbidity: a prospective randomized trial. Journal of Otolaryngology 1995;24(4):230‐3. - PubMed
Zoppi 2001 {published data only}
    1. Zoppi G, Cinquetti M, Benini A, Bonamini E, Minelli EB. Modulation of the intestinal ecosystem by probiotics and lactulose in children during treatment with ceftriaxone. Current Therapeutic Research 2001;62(5):418‐35.

References to ongoing studies

NCT02722993 {published and unpublished data}
    1. NCT02722993. Efficacy of a Probiotic Product in Children With Antibiotic‐associated Gastrointestinal Disorders. clinicaltrials.gov/ct2/show/NCT02722993 30 March 2016.
NCT02765217 {published and unpublished data}
    1. NCT02765217. Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic‐associated Diarrhea in Children (PEARL) [Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic‐associated Diarrhea in Children: Prospective, Multi‐center, Randomize, Parallel Group Placebo Controlled Clinical Trial]. clinicaltrials.gov/ct2/show/NCT02765217 6 May 2016.
NCT02993419 {published data only}
    1. NCT02993419. Bacillus Particles Prevent Children Antibiotics Associated Diarrhea [Bacillus Particles Prevent More Children's Antibiotic‐associated Diarrhea (AAD), Randomized, Double‐blind, Controlled Clinical Trial]. clinicaltrials.gov/ct2/show/NCT02993419 15 December 2016.
NCT03181516 {published data only}
    1. NCT03181516. Efficacy and Safety of BB‐12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics (PLAY ON). clinicaltrials.gov/ct2/show/NCT03181516 8 June 2017.
NCT03334604 {published and unpublished data}
    1. NCT03334604. The Effect of a Multispecies Probiotic on Reducing the Incidence of Antibiotic‐associated Diarrhoea in Children. clinicaltrials.gov/ct2/show/NCT03334604 7 November 2017.

Additional references

Akl 2009
    1. Akl EA, Briel M, You JJ, Lamontagne F, Gangji A, Cukierman‐Yaffe T, et al. LOST to follow‐up Information in Trials (LOST‐IT): a protocol on the potential impact. Trials 2009;10:40. - PMC - PubMed
Bafeta 2018
    1. Bafeta A, Koh M, Riveros C, Ravaud P. Harms Reporting in Randomized ControlledTrials of Interventions Aimed at Modifying Microbiota: A Systematic Review. Ann Intern Med 2018 Aug 21;169(4):240‐7. - PubMed
Bartlett 1978
    1. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic‐associated pseudomembranous colitis due to toxin‐producing clostridia. New England Journal of Medicine 1978;298(10):531‐4. - PubMed
Berrington 2004
    1. Berrington A, Borriello SP, Brazier J, Duckworth G, Foster K, Freeman R, et al. National Clostridium difficile Standards Group: Report to the Department of Health. Journal of Hospital Infection 2004;56 Suppl 1:1‐38. - PubMed
Bin‐Nun 2005
    1. Bin‐Nun A, Bromiker R, Wilschanski M, Kaplan M, Rudensky B, Caplan M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. Journal of Pediatrics 2005;147(2):192‐6. - PubMed
Borriello 2003
    1. Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, et al. Safety of probiotics that contain Lactobacilli or Bifidobacteria. Clinical Infectious Diseases 2003;36(3):775‐80. - PubMed
Cremonini 2002
    1. Cremonini F, Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, et al. Meta‐analysis: the effect of probiotic administration on antibiotic‐associated diarrhoea. Alimentary Pharmacology and Therapeutics 2002;16(8):1461‐7. - PubMed
Cunningham‐Rundles 2000
    1. Cunningham‐Rundles S, Ahrne S, Bengmark S, Johann‐Liang R, Marshall F, Metakis L, et al. Probiotics and immune response. American Journal of Gastroenterology 2000;95(1 Suppl):S22‐5. - PubMed
D'Souza 2002
    1. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in the prevention of antibiotic associated diarrhoea: meta‐analysis. BMJ 2002;324(7350):1361‐6. - PMC - PubMed
Davis 2010
    1. Davis LM, Martinez I, Walter J, Hutkins R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. International Journal of Food Microbiology 2010;144(2):285‐92. - PubMed
Didary 2014
    1. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. A systematic review of the safety of probiotics. Expert Opinion on Drug Safety 2014;13(2):227‐39. - PubMed
Duval 2001
    1. Duval S, Tweedie R. Trim and fill: A simple funnel‐plot‐based method of testing and adjusting for publication bias in meta‐analysis. Biometrics 2001;56(2):455‐63. - PubMed
Elstner 1983
    1. Elstner CL, Lindsay AN, Book LS, Matsen JM. Lack of relationship of Clostridium difficile to antibiotic‐associated diarrhea in children. Pediatric Infectious Disease 1983;2(5):364‐6. - PubMed
Ferreira 2007
    1. Ferreira‐González I, Busse JW, Heels‐Ansdell D, Montori VM, Akl EA, Bryant DM, et al. Problems with use of composite end points in cardiovascular trials:systematic review of randomised controlled trials. BMJ 2007;334(7597):786. - PMC - PubMed
Gibson 1998
    1. Gibson GR. Dietary modulation of the human gut microflora using prebiotics. British Journal of Nutrition 1998;80(4):S209‐12. - PubMed
Gibson 2004
    1. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota: Updating the concept of prebiotics. Nutrition Research Reviews 2004;17(2):259‐75. - PubMed
Gogate 2005
    1. Gogate A, De A, Nanivadekar R, Mathur M, Saraswathi K, Jog A, et al. Diagnostic role of stool culture and toxin detection in antibiotic associated diarrhoea due to Clostridium difficile in children. Indian Journal of Medical Research 2005;122(6):518‐24. - PubMed
Goldin 1998
    1. Goldin BR. Health benefits of probiotics. British Journal of Nutrition 1998;80(4):S203‐7. - PubMed
Guyatt 2008
    1. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck‐Ytter Y, Schünemann HJ, et al. What is "quality of evidence" and why is it important to clinicians?. BMJ 2008;336(7651):995‐8. - PMC - PubMed
Hammerman 2006
    1. Hammerman C, Bin‐Nun A, Kaplan M. Safety of probiotics: comparison of two popular strains. BMJ 2006;333(7576):1006‐8. - PMC - PubMed
Hartling 2009
    1. Hartling L, Ospina M, Liang Y, Dryden DM, Hooton N, Krebs Seida J, et al. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. BMJ 2009;339:b4012. - PMC - PubMed
Hassan 2018
    1. Hassan H, Rompola M, Glaser AW, Kinsey SE, Phillips RS. Systematic review and meta‐analysis investigating the efficacy and safety of probiotics in people with cancer. Support Care Cancer 2018;26(8):2503‐9. - PubMed
Hata 1988
    1. Hata D, Yoshida A, Ohkubo H, Mochizuki Y, Hosoki Y, Tanaka R, et al. Meningitis caused by bifidobacterium in an infant. Pediatric Infectious Disease Journal 1988;7(9):669‐71. - PubMed
Hempel 2011
    1. Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JN, Suttorp MJ, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evidence Report/Technology Assessment 2011;200:1‐645. - PMC - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Hollis 1999
    1. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670‐4. - PMC - PubMed
Ioannidis 2004
    1. Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781‐8. - PubMed
Janda 2007
    1. Janda JM, Abbott SL. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. Journal of Clinical Microbiology 2007;45(9):2761‐4. - PMC - PubMed
Johnston 2006
    1. Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic‐associated diarrhea: a meta‐analysis of randomized placebo‐controlled trials. CMAJ: Canadian Medical Association Journal 2006;175(4):377‐83. - PMC - PubMed
Johnston 2010
    1. Johnston BC, Shamseer L, Costa BR, Tsuyuki RT, Vohra S. Measurement issues in trials of pediatric acute diarrheal diseases: a systematic review. Pediatrics 2010;126(1):e222‐31. - PubMed
Johnston 2013
    1. Johnston BC, Donen R, Pooni A, Pond J, Xie F, Giglia L, et al. Conceptual framework for health‐related quality of life assessment in acute gastroenteritis. Journal of Pediatric Gastroenterology and Nutrition 2013;56(3):280‐9. - PubMed
Kale‐Pradhan 2010
    1. Kale‐Pradhan PB, Jassal HK, Wilhelm SM. Role of Lactobacillus in the prevention of antibiotic‐associated diarrhea: a meta‐analysis. Pharmacotherapy 2010;30(2):119‐26. - PubMed
Land 2005
    1. Land MH, Rouster‐Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115(1):178‐81. - PubMed
Lin 2005
    1. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005;115(1):1‐4. - PubMed
Mackay 1999
    1. Mackay AD, Taylor MB, Kibbler CC, Hamilton‐Miller JM. Lactobacillus endocarditis caused by a probiotic organism. Clinical Microbiology and Infection 1999;5(5):290‐2. - PubMed
Madsen 2001
    1. Madsen KL. The use of probiotics in gastrointestinal disease. Canadian Journal of Gastroenterology 2001;15(12):817‐22. - PubMed
McFarland 1998
    1. McFarland LV. Epidemiology, risk factors and treatments for antibiotic‐associated diarrhea. Digestive Diseases 1998;16(5):292‐307. - PubMed
McFarland 2006
    1. McFarland LV. Meta‐analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. American Journal of Gastroenterology 2006;101(4):812‐22. - PubMed
McFarland 2008
    1. McFarland LV. Antibiotic‐associated diarrhea: epidemiology, trends and treatment. Future Microbiology 2008;3(5):563‐78. - PubMed
McFarland 2010
    1. McFarland LV. Systematic review and meta‐analysis of Saccharomyces boulardiii adult patients. World Journal of Gastroenterology 2010;16(18):2202‐22. - PMC - PubMed
McFarland 2015
    1. McFarland LV. Deciphering meta‐analytic results: a mini‐review of probiotics for the prevention of paediatric antibiotic‐associated diarrhoea and Clostridium difficile infections. Beneficial Microbes 2015;6(2):189‐94. - PubMed
Mclnnes 2010
    1. McInnes P, Cutting M. Manual of procedures for human microbiome project: Core microbiome sampling, protocol A. www.ncbi.nlm.nih.gov/projects/gap/cgi‐bin/GetPdf.cgi?id=phd002854.2 (accessed 5 December 2018).
Ouwehand 2017
    1. Ouwehand AC. A review of dose‐responses of probiotics in human studies. Beneficial Microbes 2017;8(2):143‐51. - PubMed
Owens 2008
    1. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial‐associated risk factors for Clostridium difficile infection. Clinical Infectious Diseases 2008;46 Suppl 1:S19‐31. - PubMed
Piarroux 1999
    1. Piarroux R, Millon L, Bardonnet K, Vagner O, Koenig H. Are live Saccharomyces yeasts harmful to patients?. Lancet 1999;353(9167):1851‐2. - PubMed
Rautio 1999
    1. Rautio M, Jousimies‐Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clinical Infectious Diseases 1999;28(5):1159‐60. - PubMed
Raza 1995
    1. Raza S, Graham SM, Allen SJ, Sultana S, Cuevas L, Hart CA. Lactobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan. Pediatric Infectious Disease Journal 1995;14(2):107–11. - PubMed
Roberfroid 1998
    1. Roberfroid MB. Prebiotics and synbiotics: concepts and nutritional properties. British Journal of Nutrition 1998;80(4):S197‐202. - PubMed
Saavedra 1999
    1. Saavedra JM. Probiotics plus antibiotics: regulating our bacterial environment. Journal of Pediatrics 1999;135(5):535‐7. - PubMed
Salminen 1998
    1. Salminen S, Wright A, Morelli L, Marteau P, Brassart D, Vos WM, et al. Demonstration of safety of probiotics ‐‐ a review. International Journal of Food Microbiology 1998;44(1‐2):93‐106. - PubMed
Salminen 2004
    1. Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clinical Infectious Diseases 2004;38(1):62‐9. - PubMed
Saxelin 1996
    1. Saxelin M, Chuang NH, Chassy B, Rautelin H, Makela PH, Salminen S, et al. Lactobacilli and bacteremia in southern Finland, 1989‐1992. Clinical Infectious Diseases 1996;22(3):564‐6. - PubMed
Sazawal 2006
    1. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta‐analysis of masked, randomised, placebo‐controlled trials. Lancet Infectious Diseases 2006;6(6):374‐82. - PubMed
Schrezenmeir 2001
    1. Schrezenmeir J, Vrese M. Probiotics, prebiotics, and synbiotics ‐‐ approaching a definition. American Journal of Clinical Nutrition 2001;73(2 Suppl):361S‐4S. - PubMed
Sterne 2011
    1. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ 2011;343:d4002. - PubMed
Suez 2018
    1. Suez J, Zmora N, Zilberman‐Schapira G, Mor U, Dori‐Bachash M, Bashiardes S, et al. Post‐Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probioticsand Improved by Autologous FMT. Cell 2018;174(6):1406‐1423, e1‐e6. - PubMed
Sun 2014
    1. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users' guide to the medical literature. JAMA 2014;311(4):405‐11. - PubMed
Sussman 1986
    1. Sussman JI, Baron EJ, Goldberg SM, Kaplan MH, Pizzarello RA. Clinical manifestations and therapy of Lactobacillus endocarditis: report of a case and review of the literature. Reviews of Infectious Diseases 1986;8(5):771‐6. - PubMed
Szajewska 2005
    1. Szajewska H, Mrukowicz J. Meta‐analysis: non‐pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea. Alimentary Pharmacology and Therapeutics 2005;22(5):365‐72. - PubMed
Szajewska 2006
    1. Szajewska H, Ruszczyński M, Radzikowski A. Probiotics in the prevention of antibiotic‐associated diarrhea in children: a meta‐analysis of randomized controlled trials. Journal of Pediatrics 2006;149(3):367‐72. - PubMed
Szajewska 2015
    1. Szajewska H, Kołodziej M. Systematic review with meta‐analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic‐associated diarrhoea in children and adults. Alimentary Pharmacology & Therapeutics 2015;42(10):1149‐57. - PubMed
Turck 2003
    1. Turck D, Bernet JP, Marx J, Kempf H, Giard P, Walbaum O, et al. Incidence and risk factors for of oral antibiotic‐associated diarrhea in an outpatient pediatric population. Journal of Pediatric Gastroenterology and Nutrition 2003;37(1):22‐6. - PubMed
Whelan 2010
    1. Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. American Journal of Clinical Nutrition 2010;91(3):687‐703. - PubMed
Wistrom 2001
    1. Wistrom J, Norrby SR, Myhre EB, Eriksson S, Granstrom G, Lagergren L, et al. Frequency of antibiotic‐associated diarrhoea in 2462 antibiotic‐treated hospitalized patients: a prospective study. Journal of Antimicrobial Chemotherapy 2001;47(1):43‐50. - PubMed

References to other published versions of this review

Goldenberg 2015
    1. Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic‐associated diarrhea. Cochrane Database of Systematic Reviews 2015, Issue 12. [DOI: 10.1002/14651858.CD004827.pub4] - DOI - PubMed
Johnston 2007
    1. Johnston BC, Supina AL, Ospina M, Vohra S. Probiotics for the prevention of pediatric antibiotic‐associated diarrhea. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004827.pub2] - DOI - PubMed
Johnston 2011
    1. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. Probiotics for the prevention of pediatric antibiotic‐associated diarrhea. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD004827.pub3] - DOI - PubMed

Publication types

Substances